Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Dual-targeting BCMA/CD19 CAR-T therapy in patients with R/R MM

Juan Du • 13 Jun 2022
EHA 2022
Multiple Myeloma CAR-T

Juan Du, MD, Changzheng Hospital, The Second Military Medical University, Shanghai, China, shares some key results from a study evaluating BCMA/CD19 dual-targeting CAR-T therapy in patients with relapsed/refractory (R/R) multiple myeloma (MM). Dr Du first highlights the novel platform used in the production of this CAR-T agent, and then comments on the promising results observed in patients, including overall response rates (ORR) and measurable residual disease (MRD) negative responses. To conclude, Dr Du highlights the safety profile and pharmacokinetics of this agent. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Juan Du

1:56
Treatment options for myeloma patients who relapse after BCMA-directed therapies
Juan Du • 13 Jun 2022
1:24
The use of single-cell RNA sequencing to analyze patient response to CAR-T
Juan Du • 13 Jun 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals